TGFB1 and neoplasm: Minimal inhibition of VEGFR2 leads to enhanced infiltration of immunocytes, promoting CD8+ T-lymphocytes to secrete osteopontin, which in turn induces tumor cells to produce TGF-β, upregulating PD-1 levels in immunocytes and thereby improving the effectiveness of ICIs (74).